HUTCHMED's NDA For Fruquintinib-sintilimab Combo In Renal Cancer Accepted By China's NMPA
5/6 02:40
(RTTNews) - HUTCHMED (China) Limited (HCM) and Innovent Biologics, Inc. announced that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior tr...